Cue Biopharma, Inc. (FRA:1UC)

Market Cap	22.06M -74.5%
Revenue (ttm)	6.05M -25.5%
Net Income	-32.12M
EPS	-0.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187
Average Volume	431
Open	0.2350
Previous Close	0.2520
Day's Range	0.2350 - 0.2435
52-Week Range	0.2065 - 1.3300
Beta	n/a
RSI	41.20
Earnings Date	Mar 13, 2026

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 41
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1UC

Financial Performance

In 2024, Cue Biopharma's revenue was $9.29 million, an increase of 69.16% compared to the previous year's $5.49 million. Losses were -$40.67 million, -19.83% less than in 2023.

Financial numbers in USD